ASCVD Risk Estimator Plus

Разработчик: American College of Cardiology
Скачивания
Доход

Описание

The updated ASCVD Risk Estimator Plus uses up to date science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10-year ASCVD risk.
Use the app to:
• Estimate a patient’s initial 10-year ASCVD risk using the pooled cohort equation
• Receive an individualized, risk-based, intervention approach
• Project the impact of specific interventions on a patient’s risk
• Guide clinician-patient discussion around customizing an intervention plan
• Update risk at follow-up based on a patient’s response to therapy using the Million Hearts Longitudinal model
Advice from the app is derived from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, the 2018 ACC/AHA et.al Guideline on the Management of Blood Cholesterol, the 2017 ACC/AHA et.al Guideline on High Blood Pressure in Adults, the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, and the 2016 Million Hearts Longitudinal ASCVD Risk Assessment Tool user guide. The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
Скрыть Показать больше...

Скриншоты

ASCVD Risk Estimator Plus Частые Вопросы

  • Приложение ASCVD Risk Estimator Plus бесплатное?

    Да, ASCVD Risk Estimator Plus полностью бесплатное и не содержит встроенных покупок или подписок.

  • Является ли ASCVD Risk Estimator Plus фейковым или мошенническим?

    🤔 Качество приложения ASCVD Risk Estimator Plus спорное. Некоторые пользователи довольны, в то время как другие сообщают о проблемах. Рекомендуем ознакомиться с отдельными отзывами для получения более полной картины.

    Спасибо за ваш голос

  • Сколько стоит ASCVD Risk Estimator Plus?

    Приложение ASCVD Risk Estimator Plus бесплатное.

  • Сколько зарабатывает ASCVD Risk Estimator Plus?

    Чтобы получить оценку дохода приложения ASCVD Risk Estimator Plus и другие данные AppStore, вы можете зарегистрироваться на платформе мобильной аналитики AppTail.

Оценки пользователей
Приложение еще не оценено в Португалия.
История оценок

ASCVD Risk Estimator Plus Отзывы Пользователей

Update

DrTrack13 on

Россия

“Therapy impact” is not active after the last update.

Doesn't mention bariatric surgery.

mmmmnbdhdjchdhshdbd on

Соединенные Штаты

Should include bariatric surgery recommendations for patients that qualify. There are quite a few studies looking at CV risk reduction after surgery. The data should be included in this app. This app appears to ignore a major factor that plays a role (obesity) in about 35% (conservatively) of patients.

Useless

Sunrayyy on

Соединенные Штаты

Not calculating, waste time

Not working any longer

Good1981game on

Соединенные Штаты

After all of the information is typed in, it is no longer calculating the current 10 yr risk percentage.

Entered age 50, got error

mikephl on

Соединенные Штаты

It said the age had to be between 40 and 71

App needs updating

Jazmac on

Соединенные Штаты

Please update the app to reflect that aspirin is no longer indicated for primary prevention!

Defective

BigGuy57 on

Соединенные Штаты

The app returns an estimated risk based on current data. However the Therapy impact suggests various scenarios that are imprudent. Start HBP meds when the patient doesn’t have HBP. Or intensify Statins for patients whose risk is less than 7.5%

Totally inaccurate

jjmdoc on

Соединенные Штаты

This new version has some serious flaws. In addition to being harder to navigate than previous versions, it gives seriously incorrect values for ASCVD risk - last two patients I profiled both came back at 1.1% 10 year risk which is just not possible in the population I am seeing. Last person had a total cholesterol of 334! And still came back as 1.1% risk. Please scrap this version and go back to the old one.

I miss old version

teresa,np on

Соединенные Штаты

I miss the old version which included more details on statins with high/moderate vs low intensity statins. A little harder to use now.

Useful app

Internal Med Doc on

Соединенные Штаты

The estimation of therapy impact is useful and can be shown to patients so they understand rationale of treatment. The biggest fault is that fields requiring numerical data defaults to letter keyboard. It should automatically bring up the numerical keyboard to ease the burden of data entry.

Оценки

История позиций в топах
История рейтингов пока не доступна
Позиции в категории
Рейтинг
Категория
Позиция
Топ бесплатных
132
Топ бесплатных
271
Топ бесплатных
272
Топ бесплатных
276
Топ бесплатных
318

ASCVD Risk Estimator Plus Конкуренты

Name
Sanford Guide
Infectious Diseases Treatment
USPSTF Prevention TaskForce
USPSTF Recommendations (ePSS)
ASCCP Management Guidelines
CDC Vaccine Schedules
VisualDx
Medical images & differentials
DynaMed
Confidence in Practice
Contraception
STI Tx Guide
ADA Standards of Care
AHA Guidelines On-The-Go

ASCVD Risk Estimator Plus Установки

30дн.

ASCVD Risk Estimator Plus Доход

30дн.

ASCVD Risk Estimator Plus Доходы и Загрузки

Получите ценные инсайты о производительности ASCVD Risk Estimator Plus с помощью нашей аналитики.
Зарегистрируйтесь сейчас, чтобы получить доступ к статистика загрузок и доходов и многому другому.

Информация о приложении

Категория
Medical
Разработчик
American College of Cardiology
Языки
English
Последнее обновление
6.2.1 (7 месяцев назад )
Выпущено
Feb 10, 2014 (10 лет назад )
Обновлено
4 дня назад
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.